BRAFV600E mutation analysis by immunohistochemistry In patients with thoracic metastases from colorectal cancer

Pathology

Volumn 46, Issue 4, 2014, Pages 311-315

  Ilie, Marius I ^a,b,c   Long Mira, Elodie ^a,b   Hofman, Véronique ^a,b,c   Mouroux, Jérôme ^a,b   Vignaud, Jean Michel ^d   Gauchotte, Guillaume ^d   Begueret, Hugues ^e   Merlio, Jean Philippe ^e   Emile, Jean François ^f,g   Hébuterne, Xavier ^a,h   Hofman, Paul ^a,b,c  

^a UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^b PASTEUR HOSPITAL   (France)

^c Cancer Research Association (ARC)   (France)

^d CHU NANCY BRABOIS   (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f HÔPITAL AMBROISE PARÉ   (France)

^g LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Immunohistochemistry; Metastatic colorectal carcinoma; Targeted therapy

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADENOCARCINOMA; AGED; COLORECTAL TUMOR; DIAGNOSTIC USE; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MORTALITY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; PROGNOSIS; SECONDARY; SENSITIVITY AND SPECIFICITY; THORAX TUMOR; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SENSITIVITY AND SPECIFICITY; THORACIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902150803     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000113     Document Type: Article

References (42)

1. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
2. Lin JS, Webber EM, Senger CA, et al. Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. Am J Cancer Res 2011;1:650-62.
3. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361:98-9.
4. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.
5. Farina-Sarasqueta A, Van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010;21:2396-402.
6. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009;27:5924-30.
7. Mao C, Liao RY, Qiu LX, et al. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Mol Biol Rep 2011;38:2219-23.
8. Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009;101:465-72.
9. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72.
10. Yokota T, Ura T, Shibata N, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011;104:856-62.
11. Xu Q, Xu AT, Zhu MM, et al. Predictive and prognostic role of BRAF mutation in patients with metastatic colorectal cancer treated with antiepidermal growth factor receptor monoclonal antibodies: a meta-analysis. J Dig Dis 2013;14:409-16.
12. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009;27:5931-7.
13. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
14. Andrulis M, Penzel R, Weichert W, et al. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 2012;36:1796-800.
15. Bosmuller H, Fischer A, Pham DL, et al. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allelespecific PCR. Hum Pathol 2013;44:329-35.
16. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011;122:11-9.
17. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1, 120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012;123:223-33.
18. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012;36:844-50.
19. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013;37:61-5.
20. Ilie M, Long E, Hofman V, et al. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013;24:742-8.
21. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-9.
22. Molinari F, Martin V, Saletti P, et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 2009;100:1087-94.
23. Scartozzi M, Bearzi I, Berardi R, et al. Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. Br J Cancer 2007;97:92-7.
24. Heinzerling L, Baiter M, Kuhnapfel S, et al. Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. Br J Cancer 2013;109:2833-41.
25. Boursault L, Haddad V, Vergier B, et al. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS One 2013;8:e70826.
26. Shimizu K, Yukawa T, Hirami Y, et al. Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer. Target Oncol 2013;8:237-42.
27. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
28. Burrell RA, McGranahan N, Bartek J, et al. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338-45.
29. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413-21.
30. Gonzalez De Castro D, Angulo B, Gomez B, et al. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br J Cancer 2012;107:345-51.
31. Kumar R, Angelini S, Czene K, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003;9:3362-8.
32. Capper D, Voigt A, Bozukova G, et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer 2013;133:1624-30.
33. Blank PR, Moch H, Szucs TD, et al. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res 2011;17:6338-46.
34. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-9.
35. Mostert B, Jiang Y, Sieuwerts AM, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer 2013;133:130-41.
36. Yaeger R, Saltz L. BRAF mutations in colorectal cancer: clinical relevance and role in targeted therapy. J Natl Compr Canc Netw 2012;10:1456-8.
37. Ilie M, Hofman P. The potential value of immunohistochemistry as a screening tool for oncogenic targets of personalized lung cancer therapy. J Oncopathol 2013;1:1.
38. Adackapara CA, Sholl LM, Barletta JA, et al. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology 2013;63:187-93.
39. Toon CW, Walsh MD, Chou A, et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol 2013;37:1592-602.
40. Marin C, Beauchet A, Capper D, et al. Detection of BRAF p. V600E mutations on melanoma by immunohistochemistry has a good interobserver reproducibility. Arch Pathol Lab Med 2014;138:71-5.
41. Bullock M, O'Neill C, Chou A, et al. Utilization of a MAB for BRAF (V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 2012;19:779-84.
42. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.